What is Haemonetics's debt issuance costs?

Haemonetics (HAE) reported debt issuance costs of $0 in Q1 2026.

What is the long-term trend for Haemonetics's debt issuance costs?

Over 2 years (2023 to 2026), Haemonetics's debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Haemonetics HAE Debt Issuance Costs

Debt Issuance Costs at other companies

TFX

TeleflexTFX

$0-100%

RepligenRGEN

$0—

RevvityRVTY

$0-100%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Haemonetics's debt issuance costs?: Haemonetics (HAE) reported debt issuance costs of $0 in Q1 2026.
What is the long-term trend for Haemonetics's debt issuance costs?: Over 2 years (2023 to 2026), Haemonetics's debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.